curacle co.,ltd. (KOSDAQ:365270)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,770
+1,180 (7.11%)
At close: Apr 27, 2026
160.56%
Market Cap 373.89B
Revenue (ttm) 7.10M
Net Income (ttm) -18.11B
Shares Out 21.30M
EPS (ttm) -1,120.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 450,446
Average Volume 236,927
Open 16,770
Previous Close 16,590
Day's Range 16,770 - 18,190
52-Week Range 3,600 - 20,750
Beta 2.28
RSI 62.60
Earnings Date n/a

About curacle co.,ltd.

curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company’s products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- β/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 365270
Full Company Profile

Financial Performance

In 2025, curacle co.,ltd.'s revenue was 7.10 million, a decrease of -99.57% compared to the previous year's 1.63 billion. Losses were -18.11 billion, 21.7% more than in 2024.

Financial Statements

News

There is no news available yet.